- Home
- GLPG vs TDC Comparison
GLPG vs TDC Comparison
Compare GLPG & TDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- TDC
- Stock Information
- Founded
- GLPG 1999
- TDC 1979
- Country
- GLPG Belgium
- TDC United States
- Employees
- GLPG N/A
- TDC N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- TDC Computer Software: Prepackaged Software
- Sector
- GLPG Health Care
- TDC Technology
- Exchange
- GLPG Nasdaq
- TDC Nasdaq
- Market Cap
- GLPG 2.1B
- TDC 2.1B
- IPO Year
- GLPG 2005
- TDC 2007
- Fundamental
- Price
- GLPG $34.45
- TDC $21.61
- Analyst Decision
- GLPG Sell
- TDC Buy
- Analyst Count
- GLPG 3
- TDC 7
- Target Price
- GLPG $26.00
- TDC $29.67
- AVG Volume (30 Days)
- GLPG 203.5K
- TDC 1.2M
- Earning Date
- GLPG 10-29-2025
- TDC 11-03-2025
- Dividend Yield
- GLPG N/A
- TDC N/A
- EPS Growth
- GLPG N/A
- TDC 79.70
- EPS
- GLPG N/A
- TDC 1.13
- Revenue
- GLPG $323,674,692.00
- TDC $1,675,000,000.00
- Revenue This Year
- GLPG $1.77
- TDC N/A
- Revenue Next Year
- GLPG $0.44
- TDC N/A
- P/E Ratio
- GLPG N/A
- TDC $19.53
- Revenue Growth
- GLPG 5.43
- TDC N/A
- 52 Week Low
- GLPG $22.36
- TDC $18.43
- 52 Week High
- GLPG $37.78
- TDC $33.69
- Technical
- Relative Strength Index (RSI)
- GLPG 53.87
- TDC 50.04
- Support Level
- GLPG $32.37
- TDC $21.33
- Resistance Level
- GLPG $37.78
- TDC $23.18
- Average True Range (ATR)
- GLPG 0.77
- TDC 0.73
- MACD
- GLPG 0.00
- TDC -0.03
- Stochastic Oscillator
- GLPG 39.37
- TDC 25.66
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About TDC Teradata Corporation
Teradata Corp focused on helping organizations improve business performance, enrich customer experiences, and integrate data across the enterprise. The company's platform provides companies with Harmonized Data: Trusted AI: Teradata VantageCloud: Teradata VantageCore: ClearScape Analytics: and Query Grid. The company generates majority of revenue from the United States.